Dicerna Pharmaceuticals, Inc.

Silver

Information

Dicerna develops medicines that leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease.  

Dicerna’s lead RNAi therapeutic candidate, nedosiran, is in development for the treatment of primary hyperoxaluria (PH), a family of ultra-rare genetic disorders that can lead to life-threatening kidney damage.    

Interest
PediatricsUrolithiasis/Endourology

Social media

Contact details

Documents & Links